
GIST, or gastrointestinal stromal tumour, is a cancer of the GI tract. It most often occurs in the stomach and small intestine. The tumours originate from specialised cells called interstitial cells of Cajal, which coordinate contractions of the smooth muscle in the digestive system.
Causes
Risk Factors:
The medical treatment of Gastrointestinal Stromal Tumor (GIST) in India adapts the newest research and technologies to meet worldwide clinical standards and healthcare capabilities.
The medical treatment for Gastrointestinal Stromal Tumor (GIST) requires evaluating the patient's severity and medical condition. The following are the treatment options:
Surgery: In localised cases of GIST, surgical resection is the best option. The tumour should be resectable; the patient would be cured by a total resection under the best circumstances. Complications are more evident with larger tumours or those situated in areas that are technically challenging to access.
Targeted Therapy (TKIs) is the principal treatment modality for an advanced or metastatic GIST, targeting KIT and PDGFRA mutations. These agents exert their effect mainly on the intrinsic growth of the tumour cell and its ability to spread.
Cost Start From USD 8000 - USD 12000Explore Options
Radiation Therapy: Radiation therapy for GIST treatment is not the standard due to GISTs being relatively resistant to it. It may be offered in rare instances for symptomatic relief or when surgery is contraindicated, such as for pain or obstruction.
Chemotherapy : Chemotherapy is usually ineffective for GISTs. Chemotherapy does not form a part of the treatment since GISTs respond poorly to familiar chemotherapeutic agents.
Cost Start From USD 600 - USD 700Explore Options
Immunotherapy and New Agents: Immunotherapy and new drugs are still being studied to treat resistant GISTs. Medications offer hope for the overcoming of resistance and improvement in treatment results.
Cost Start From USD 3000 - USD 5000Explore Options
These are the standard diagnostic methods for diagnosing Gastrointestinal Stromal Tumor (GIST):
MediRehab (chain of Rehab centres - part of MediGence provides comprehensive rehabilitation services designed to support patients in India. Additional services are as per the patient's requirement. These services include:









Hyderabad, India
Apollo Hospitals located in Hyderabad, India is accredited by JCI, NABH. Also listed below are some of the most prominent infrastructural details:

Hyderabad, India
Star Hospitals located in Hyderabad, India is accredited by NABH, NABL. Also listed below are some of the most prominent infrastructural details:

Mumbai, India
Sterling Wockhardt Hospital located in Mumbai, India is accredited by NABH. Also listed below are some of the most prominent infrastructural details:
Opinion & Option
We submit the most accurate opinion and options from one or more countries for your review
Consult Privately
Consult with a certified specialist privately on our telemedicine platform even before you decide to travel
Logistics
We handle flights, visas, transfers, and accommodation—so you can focus on your health.
Recovery
Our In-house rehabilitation service packages to better your recovery and treatment outcome
The following are the much-growing reasons for India being frequented for Gastrointestinal Stromal Tumor (GIST) treatment:
Since most GISTs are linked to genetic mutations, nothing is known to prevent them. Genetic counselling and screening will, however, aid in early detection if a family history with inherited conditions increases risk.
The prognosis of GISTs depends on several factors: the size and location of the tumour, the specific mutation type, and the degree of spread. Early-stage GISTs, when resected surgically, place their patients in a better prognostic category, while advanced ones require long-term therapy by medications.
Yes, GISTs can return, especially when the original tumour was large or had specific genetic mutation patterns. Therefore, regular follow-up imaging care is essential to detect these at the earliest signs of recurrence or metastasis.
The side effects from treatment, especially tyrosine kinase inhibitors (TKIs), can include fatigue, nausea, swelling, muscle cramps, and impairment of liver functions. These side effects should be controlled and managed according to the directions of the treating physician.
Novel medications have been established for treating GISTs that are resistant to other therapies, while studies are going on to combine targeted therapies with immunotherapy for improved management of advanced GISTs.
GISTs are clinically uncommon in India, but their incidence has increased due to better awareness, improved diagnostic techniques, and access to health care. They are usually seen in adults, with the stomach being the most common site of GISTs.
The survival rate for GIST in India is mainly dependent on when the disease is diagnosed and at what stage of cancer the patient is. In early-stage GIST, the prognosis is excellent, especially in surgical cases. However, for late-stage or metastatic GIST, doctors opt for targeted therapies, which help in improving survival rates, though quite a bit of long-term management would be needed.
Several premier cancer hospitals in India specialise in managing Gastrointestinal Stromal Tumors (GISTs). These hospitals provide supportive management, including surgery, chemotherapy, targeted therapy, and follow-up management.